000063275 001__ 63275
000063275 005__ 20200221144234.0
000063275 0247_ $$2doi$$a10.1093/infdis/jiw228
000063275 0248_ $$2sideral$$a96681
000063275 037__ $$aART-2016-96681
000063275 041__ $$aeng
000063275 100__ $$aScriba, Thomas J.
000063275 245__ $$aVaccination against tuberculosis with whole-cell mycobacterial vaccines
000063275 260__ $$c2016
000063275 5060_ $$aAccess copy available to the general public$$fUnrestricted
000063275 5203_ $$aLive attenuated and killed whole-cell vaccines (WCVs) offer promising vaccination strategies against tuberculosis. A number of WCV candidates, based on recombinant bacillus Calmette-Guerin (BCG), attenuated Mycobacterium tuberculosis, or related mycobacterial species are in various stages of preclinical or clinical development. In this review, we discuss the vaccine candidates and key factors shaping the development pathway for live and killed WCVs and provide an update on progress.
000063275 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/BIO2014-5258P$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 643381-TBVAC2020$$9info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020$$9info:eu-repo/grantAgreement/EC/FP7/241745/EU/Discovery and preclinical development of new generation tuberculosis vaccines/NEWTBVAC
000063275 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000063275 590__ $$a6.273$$b2016
000063275 591__ $$aIMMUNOLOGY$$b23 / 150 = 0.153$$c2016$$dQ1$$eT1
000063275 591__ $$aMICROBIOLOGY$$b15 / 124 = 0.121$$c2016$$dQ1$$eT1
000063275 591__ $$aINFECTIOUS DISEASES$$b7 / 84 = 0.083$$c2016$$dQ1$$eT1
000063275 592__ $$a3.931$$b2016
000063275 593__ $$aInfectious Diseases$$c2016$$dQ1
000063275 593__ $$aImmunology and Allergy$$c2016$$dQ1
000063275 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000063275 700__ $$aKaufmann, Stefan H. E.
000063275 700__ $$aLambert, Paul Henri
000063275 700__ $$aSanicas, Melvin
000063275 700__ $$0(orcid)0000-0003-2993-5478$$aMartin, Carlos$$uUniversidad de Zaragoza
000063275 700__ $$aNeyrolles, Olivier
000063275 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología
000063275 773__ $$g214, 5 (2016), 659-664 [22 pp]$$pJ. infect. dis.$$tJOURNAL OF INFECTIOUS DISEASES$$x0022-1899
000063275 8564_ $$s1072352$$uhttps://zaguan.unizar.es/record/63275/files/texto_completo.pdf$$yPostprint
000063275 8564_ $$s53422$$uhttps://zaguan.unizar.es/record/63275/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000063275 909CO $$ooai:zaguan.unizar.es:63275$$particulos$$pdriver
000063275 951__ $$a2020-02-21-13:20:16
000063275 980__ $$aARTICLE